<antigenSupportingData>
    <immunity>
    </immunity>
    <contraindications>
        <vaccineGroup>
            <contraindication>
                <observationCode>122</observationCode>
                <observationTitle>Severe allergic reaction after previous dose of COVID-19</observationTitle>
                <contraindicationText>Do not vaccinate if the patient has had a severe allergic reaction after a previous dose of COVID-19 vaccine.</contraindicationText>
                <contraindicationGuidance/>
                <beginAge/>
                <endAge/>
            </contraindication>
            <contraindication>
                <observationCode>080</observationCode>
                <observationTitle>Adverse reaction to vaccine component</observationTitle>
                <contraindicationText>Do not vaccinate if the patient has had an adverse reaction to a vaccine component.</contraindicationText>
                <contraindicationGuidance/>
                <beginAge/>
                <endAge/>
            </contraindication>
        </vaccineGroup>
        <vaccine>
            <contraindication>
                <observationCode>187</observationCode>
                <observationTitle>Allergic reaction to polysorbate 80</observationTitle>
                <contraindicationText>Do not vaccinate if the patient has had an immediate allergic reaction of any severity to polysorbate 80.</contraindicationText>
                <contraindicationGuidance/>
                <contraindicatedVaccine>
                    <vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
                    <cvx>212</cvx>
                    <beginAge/>
                    <endAge/>
                </contraindicatedVaccine>
            </contraindication>
            <contraindication>
                <observationCode>188</observationCode>
                <observationTitle>Known allergy to Polyethylene glycol [PEG]</observationTitle>
                <contraindicationText>Do not vaccinate if the patient has known allergy to Polyethylene glycol [PEG].</contraindicationText>
                <contraindicationGuidance/>
                <contraindicatedVaccine>
                    <vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
                    <cvx>207</cvx>
                    <beginAge/>
                    <endAge/>
                </contraindicatedVaccine>
                <contraindicatedVaccine>
                    <vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
                    <cvx>208</cvx>
                    <beginAge/>
                    <endAge/>
                </contraindicatedVaccine>
            </contraindication>
        </vaccine>
    </contraindications>
    <series>
        <seriesName>2-dose Pfizer series</seriesName>
        <targetDisease>COVID-19</targetDisease>
        <vaccineGroup>COVID-19</vaccineGroup>
        <seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
        <seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
        <seriesAdminGuidance>Current evidence suggests that the risk of SARS-CoV-2 reinfection is low in the months after initial infection but may increase with time due to waning immunity. Thus, people with a history of MIS-C or MIS-A should consider delaying vaccination until they have recovered from illness and for 90 days after the date of diagnosis of MIS-C or MIS-A, recognizing that the risk of reinfection and, therefore, the benefit from vaccination, might increase with time following initial infection.</seriesAdminGuidance>
        <seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
        <seriesType>Standard</seriesType>
        <equivalentSeriesGroups/>
        <requiredGender/>
        <selectSeries>
            <defaultSeries>Yes</defaultSeries>
            <productPath>Yes</productPath>
            <seriesGroupName>Standard</seriesGroupName>
            <seriesGroup>1</seriesGroup>
            <seriesPriority>A</seriesPriority>
            <seriesPreference>1</seriesPreference>
            <minAgeToStart/>
            <maxAgeToStart/>
        </selectSeries>
        <indication/>
        <seriesDose>
            <doseNumber>Dose 1</doseNumber>
            <age>
                <absMinAge>0 days</absMinAge>
                <minAge>12 years</minAge>
                <earliestRecAge>12 years</earliestRecAge>
                <latestRecAge/>
                <maxAge/>
                <effectiveDate/>
                <cessationDate/>
            </age>
            <interval/>
            <allowableInterval/>
            <preferableVaccine>
                <vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
                <cvx>208</cvx>
                <beginAge>12 years</beginAge>
                <endAge/>
                <tradeName/>
                <mvx/>
                <volume>0.3</volume>
                <forecastVaccineType>N</forecastVaccineType>
            </preferableVaccine>
            <allowableVaccine>
                <vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
                <cvx>208</cvx>
                <beginAge>0 days</beginAge>
                <endAge/>
            </allowableVaccine>
            <inadvertentVaccine/>
            <conditionalSkip/>
            <recurringDose>No</recurringDose>
            <seasonalRecommendation/>
        </seriesDose>
        <seriesDose>
            <doseNumber>Dose 2</doseNumber>
            <age>
                <absMinAge>0 days</absMinAge>
                <minAge>12 years</minAge>
                <earliestRecAge>12 years</earliestRecAge>
                <latestRecAge/>
                <maxAge/>
                <effectiveDate/>
                <cessationDate/>
            </age>
            <interval>
                <fromPrevious>Y</fromPrevious>
                <fromTargetDose/>
                <fromMostRecent/>
                <fromRelevantObs/>
                <absMinInt>21 days - 4 days</absMinInt>
                <minInt>21 days</minInt>
                <earliestRecInt>21 days</earliestRecInt>
                <latestRecInt>42 days</latestRecInt>
                <intervalPriority/>
                <effectiveDate/>
                <cessationDate/>
            </interval>
            <allowableInterval>
                <fromPrevious>Y</fromPrevious>
                <fromTargetDose/>
                <absMinInt>0 days</absMinInt>
                <effectiveDate/>
                <cessationDate/>
            </allowableInterval>
            <preferableVaccine>
                <vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
                <cvx>208</cvx>
                <beginAge>12 years</beginAge>
                <endAge/>
                <tradeName/>
                <mvx/>
                <volume>0.3</volume>
                <forecastVaccineType>Y</forecastVaccineType>
            </preferableVaccine>
            <allowableVaccine>
                <vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
                <cvx>208</cvx>
                <beginAge>0 days</beginAge>
                <endAge/>
            </allowableVaccine>
            <inadvertentVaccine/>
            <conditionalSkip/>
            <recurringDose>No</recurringDose>
            <seasonalRecommendation/>
        </seriesDose>
    </series>
    <series>
        <seriesName>2-dose Moderna series</seriesName>
        <targetDisease>COVID-19</targetDisease>
        <vaccineGroup>COVID-19</vaccineGroup>
        <seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
        <seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
        <seriesAdminGuidance>Current evidence suggests that the risk of SARS-CoV-2 reinfection is low in the months after initial infection but may increase with time due to waning immunity. Thus, people with a history of MIS-C or MIS-A should consider delaying vaccination until they have recovered from illness and for 90 days after the date of diagnosis of MIS-C or MIS-A, recognizing that the risk of reinfection and, therefore, the benefit from vaccination, might increase with time following initial infection.</seriesAdminGuidance>
        <seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
        <seriesAdminGuidance>If age 12 through 17 years and Moderna vaccine inadvertently administered instead of Pfizer-BioNTech as the first dose, may administer Moderna vaccine as the second dose (as off-label use, because Moderna vaccine is not authorized in this age group).</seriesAdminGuidance>
        <seriesType>Standard</seriesType>
        <equivalentSeriesGroups/>
        <requiredGender/>
        <selectSeries>
            <defaultSeries>No</defaultSeries>
            <productPath>Yes</productPath>
            <seriesGroupName>Standard</seriesGroupName>
            <seriesGroup>1</seriesGroup>
            <seriesPriority>A</seriesPriority>
            <seriesPreference>2</seriesPreference>
            <minAgeToStart/>
            <maxAgeToStart/>
        </selectSeries>
        <indication/>
        <seriesDose>
            <doseNumber>Dose 1</doseNumber>
            <age>
                <absMinAge>0 days</absMinAge>
                <minAge>18 years</minAge>
                <earliestRecAge>18 years</earliestRecAge>
                <latestRecAge/>
                <maxAge/>
                <effectiveDate/>
                <cessationDate/>
            </age>
            <interval/>
            <allowableInterval/>
            <preferableVaccine>
                <vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
                <cvx>207</cvx>
                <beginAge>18 years</beginAge>
                <endAge/>
                <tradeName/>
                <mvx/>
                <volume>0.5</volume>
                <forecastVaccineType>N</forecastVaccineType>
            </preferableVaccine>
            <allowableVaccine>
                <vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
                <cvx>207</cvx>
                <beginAge>0 days</beginAge>
                <endAge/>
            </allowableVaccine>
            <inadvertentVaccine/>
            <conditionalSkip/>
            <recurringDose>No</recurringDose>
            <seasonalRecommendation/>
        </seriesDose>
        <seriesDose>
            <doseNumber>Dose 2</doseNumber>
            <age>
                <absMinAge>0 days</absMinAge>
                <minAge>18 years</minAge>
                <earliestRecAge>18 years</earliestRecAge>
                <latestRecAge/>
                <maxAge/>
                <effectiveDate/>
                <cessationDate/>
            </age>
            <interval>
                <fromPrevious>Y</fromPrevious>
                <fromTargetDose/>
                <fromMostRecent/>
                <fromRelevantObs/>
                <absMinInt>28 days - 4 days</absMinInt>
                <minInt>28 days</minInt>
                <earliestRecInt>28 days</earliestRecInt>
                <latestRecInt>42 days</latestRecInt>
                <intervalPriority/>
                <effectiveDate/>
                <cessationDate/>
            </interval>
            <allowableInterval>
                <fromPrevious>Y</fromPrevious>
                <fromTargetDose/>
                <absMinInt>0 days</absMinInt>
                <effectiveDate/>
                <cessationDate/>
            </allowableInterval>
            <preferableVaccine>
                <vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
                <cvx>207</cvx>
                <beginAge>18 years</beginAge>
                <endAge/>
                <tradeName/>
                <mvx/>
                <volume>0.5</volume>
                <forecastVaccineType>Y</forecastVaccineType>
            </preferableVaccine>
            <allowableVaccine>
                <vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
                <cvx>207</cvx>
                <beginAge>0 days</beginAge>
                <endAge/>
            </allowableVaccine>
            <inadvertentVaccine/>
            <conditionalSkip/>
            <recurringDose>No</recurringDose>
            <seasonalRecommendation/>
        </seriesDose>
    </series>
    <series>
        <seriesName>1-dose Janssen series</seriesName>
        <targetDisease>COVID-19</targetDisease>
        <vaccineGroup>COVID-19</vaccineGroup>
        <seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
        <seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
        <seriesAdminGuidance>Current evidence suggests that the risk of SARS-CoV-2 reinfection is low in the months after initial infection but may increase with time due to waning immunity. Thus, people with a history of MIS-C or MIS-A should consider delaying vaccination until they have recovered from illness and for 90 days after the date of diagnosis of MIS-C or MIS-A, recognizing that the risk of reinfection and, therefore, the benefit from vaccination, might increase with time following initial infection.</seriesAdminGuidance>
        <seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
        <seriesType>Standard</seriesType>
        <equivalentSeriesGroups/>
        <requiredGender/>
        <selectSeries>
            <defaultSeries>No</defaultSeries>
            <productPath>Yes</productPath>
            <seriesGroupName>Standard</seriesGroupName>
            <seriesGroup>1</seriesGroup>
            <seriesPriority>A</seriesPriority>
            <seriesPreference>3</seriesPreference>
            <minAgeToStart/>
            <maxAgeToStart/>
        </selectSeries>
        <indication/>
        <seriesDose>
            <doseNumber>Dose 1</doseNumber>
            <age>
                <absMinAge>0 days</absMinAge>
                <minAge>18 years</minAge>
                <earliestRecAge>18 years</earliestRecAge>
                <latestRecAge/>
                <maxAge/>
                <effectiveDate/>
                <cessationDate/>
            </age>
            <interval>
                <fromPrevious>N</fromPrevious>
                <fromTargetDose/>
                <fromMostRecent>207; 208; 213</fromMostRecent>
                <fromRelevantObs/>
                <absMinInt>0 days</absMinInt>
                <minInt>28 days</minInt>
                <earliestRecInt>28 days</earliestRecInt>
                <latestRecInt/>
                <intervalPriority/>
                <effectiveDate/>
                <cessationDate/>
            </interval>
            <allowableInterval/>
            <preferableVaccine>
                <vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
                <cvx>212</cvx>
                <beginAge>18 years</beginAge>
                <endAge/>
                <tradeName/>
                <mvx/>
                <volume>0.5</volume>
                <forecastVaccineType>N</forecastVaccineType>
            </preferableVaccine>
            <allowableVaccine>
                <vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
                <cvx>212</cvx>
                <beginAge>0 days</beginAge>
                <endAge/>
            </allowableVaccine>
            <inadvertentVaccine/>
            <conditionalSkip/>
            <recurringDose>No</recurringDose>
            <seasonalRecommendation/>
        </seriesDose>
    </series>
    <series>
        <seriesName>2-dose mRNA series</seriesName>
        <targetDisease>COVID-19</targetDisease>
        <vaccineGroup>COVID-19</vaccineGroup>
        <seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
        <seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
        <seriesAdminGuidance>Current evidence suggests that the risk of SARS-CoV-2 reinfection is low in the months after initial infection but may increase with time due to waning immunity. Thus, people with a history of MIS-C or MIS-A should consider delaying vaccination until they have recovered from illness and for 90 days after the date of diagnosis of MIS-C or MIS-A, recognizing that the risk of reinfection and, therefore, the benefit from vaccination, might increase with time following initial infection.</seriesAdminGuidance>
        <seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
        <seriesType>Standard</seriesType>
        <equivalentSeriesGroups/>
        <requiredGender/>
        <selectSeries>
            <defaultSeries>No</defaultSeries>
            <productPath>No</productPath>
            <seriesGroupName>Standard</seriesGroupName>
            <seriesGroup>1</seriesGroup>
            <seriesPriority>A</seriesPriority>
            <seriesPreference>4</seriesPreference>
            <minAgeToStart/>
            <maxAgeToStart/>
        </selectSeries>
        <indication/>
        <seriesDose>
            <doseNumber>Dose 1</doseNumber>
            <age>
                <absMinAge>0 days</absMinAge>
                <minAge>12 years</minAge>
                <earliestRecAge>12 years</earliestRecAge>
                <latestRecAge/>
                <maxAge/>
                <effectiveDate/>
                <cessationDate/>
            </age>
            <interval/>
            <allowableInterval/>
            <preferableVaccine>
                <vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
                <cvx>207</cvx>
                <beginAge>18 years</beginAge>
                <endAge/>
                <tradeName/>
                <mvx/>
                <volume>0.5</volume>
                <forecastVaccineType>N</forecastVaccineType>
            </preferableVaccine>
            <preferableVaccine>
                <vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
                <cvx>208</cvx>
                <beginAge>12 years</beginAge>
                <endAge/>
                <tradeName/>
                <mvx/>
                <volume>0.3</volume>
                <forecastVaccineType>N</forecastVaccineType>
            </preferableVaccine>
            <allowableVaccine>
                <vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
                <cvx>207</cvx>
                <beginAge>0 days</beginAge>
                <endAge/>
            </allowableVaccine>
            <allowableVaccine>
                <vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
                <cvx>208</cvx>
                <beginAge>0 days</beginAge>
                <endAge/>
            </allowableVaccine>
            <allowableVaccine>
                <vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
                <cvx>213</cvx>
                <beginAge>0 days</beginAge>
                <endAge/>
            </allowableVaccine>
            <inadvertentVaccine/>
            <conditionalSkip/>
            <recurringDose>No</recurringDose>
            <seasonalRecommendation/>
        </seriesDose>
        <seriesDose>
            <doseNumber>Dose 2</doseNumber>
            <age>
                <absMinAge/>
                <minAge/>
                <earliestRecAge/>
                <latestRecAge/>
                <maxAge/>
                <effectiveDate/>
                <cessationDate/>
            </age>
            <interval>
                <fromPrevious>Y</fromPrevious>
                <fromTargetDose/>
                <fromMostRecent/>
                <fromRelevantObs/>
                <absMinInt>28 days - 4 days</absMinInt>
                <minInt>28 days</minInt>
                <earliestRecInt>28 days</earliestRecInt>
                <latestRecInt>42 days</latestRecInt>
                <intervalPriority/>
                <effectiveDate/>
                <cessationDate/>
            </interval>
            <allowableInterval>
                <fromPrevious>Y</fromPrevious>
                <fromTargetDose/>
                <absMinInt>0 days</absMinInt>
                <effectiveDate/>
                <cessationDate/>
            </allowableInterval>
            <preferableVaccine>
                <vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
                <cvx>207</cvx>
                <beginAge>18 years</beginAge>
                <endAge/>
                <tradeName/>
                <mvx/>
                <volume>0.5</volume>
                <forecastVaccineType>N</forecastVaccineType>
            </preferableVaccine>
            <preferableVaccine>
                <vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
                <cvx>208</cvx>
                <beginAge>12 years</beginAge>
                <endAge/>
                <tradeName/>
                <mvx/>
                <volume>0.3</volume>
                <forecastVaccineType>N</forecastVaccineType>
            </preferableVaccine>
            <allowableVaccine>
                <vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
                <cvx>207</cvx>
                <beginAge>0 days</beginAge>
                <endAge/>
            </allowableVaccine>
            <allowableVaccine>
                <vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
                <cvx>208</cvx>
                <beginAge>0 days</beginAge>
                <endAge/>
            </allowableVaccine>
            <allowableVaccine>
                <vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
                <cvx>213</cvx>
                <beginAge>0 days</beginAge>
                <endAge/>
            </allowableVaccine>
            <inadvertentVaccine/>
            <conditionalSkip/>
            <recurringDose>No</recurringDose>
            <seasonalRecommendation/>
        </seriesDose>
    </series>
</antigenSupportingData>
